Affiliation: Harvard University
- Emerging treatment options for advanced-stage mycosis fungoidesReed E Drews
Beth Israel Deaconess Medical Center, 330 Brookline Ave, E RA 430, Boston, MA 02215
J Clin Oncol 30:4064-70. 2012..The scalp tumor has overlying epidermal change with ulceration; the face tumor is subdermal with minimal overlying epidermal change and obstructs the right external auditory meatus (Fig 1D). You consider management options...
- Genetic analysis of adenovirus E1A: induction of genetic instability and altered cell morphologic and growth characteristics are segregatable functionsR Drews
Charles A Dana Research Institute and the Harvard Thorndike Laboratory of Beth Israel Deaconess Medical Center, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Mutat Res 421:9-25. 1998....
- Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patientsReed E Drews
Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA
Clin Chest Med 24:607-22. 2003..Because of its anticoagulant effect, however, drotrecogin alfa may induce bleeding. Guidelines for drotrecogin alfa use must take into account bleeding risks...
- SMARCAD1, a novel human helicase family-defining member associated with genetic instability: cloning, expression, and mapping to 4q22-q23, a band rich in breakpoints and deletion mutants involved in several human diseasesC N Adra
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Genomics 69:162-73. 2000....
- Disparities in breast cancer treatment and survival for women with disabilitiesEllen P McCarthy
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Ann Intern Med 145:637-45. 2006..Little is known about breast cancer treatment for women with disabilities...
- Cancer stage at diagnosis and survival among persons with Social Security Disability Insurance on MedicareEllen P McCarthy
Division of General Medicine and Primary Care, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, E RO 139, Boston, MA 02215, USA
Health Serv Res 42:611-28. 2007..To examine stage at diagnosis and survival for disabled Medicare beneficiaries diagnosed with cancer under age 65 and compare their experiences with those of other persons diagnosed under age 65...
- Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancerLisa I Iezzoni
Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, MA, USA
Arch Phys Med Rehabil 89:595-601. 2008..Treatment disparities for disabled Medicare beneficiaries with stage I non-small cell lung cancer...
- Managed care and cancer outcomes for Medicare beneficiaries with disabilitiesRichard G Roetzheim
Department of Family Medicine, University of South Florida, 12901 Bruce B Downs Blvd, MDC 13, Tampa, FL 33612, USA
Am J Manag Care 14:287-96. 2008..To determine if the type of insurance arrangement, specifically health maintenance organization (HMO) vs fee-for-service (FFS), affects cancer outcomes for Medicare beneficiaries with disabilities...
- Drug-associated disease: hematologic dysfunctionErik R Vandendries
Division of Hemostasis Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
Crit Care Clin 22:347-55, viii. 2006..For example, cisplatin can cause hemolytic uremia syndrome and erythropoietin deficiency, and quinine can precipitate immune-mediated thrombocytopenia, immune-mediated thrombocytopenia, and thrombotic microangiopathy...